ShareValue scores for RXST: Valuation 64, Quality 54, Growth 58, Health 39.

Rxsight Inc logo

RXST
NASDAQ

Rxsight Inc

$6.08(-3.34%)
Loading chart...
Sentiment

Verdicts

Rating

Trap Risk

Return

4% to 18%
Valuation
64
Fair Value
Price vs Value
Quality
54
Moderate
Business Strength
Growth
58
Moderate
Revenue & Earnings
Health
39
Stressed
Financial Stability
Momentum
27
Bearish
Price Trend

Company Details

About

RxSight, Inc., a commercial-stage medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight Light Adjustable Lens (LAL), an intraocular lens made of photosensitive material that changes shape in response to specific patterns of ultraviolet, which can be adjusted to improve uncorrected visual acuity; and RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. RxSight, Inc. was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. The company was incorporated in 1997 and is headquartered in Aliso Viejo, California.

Score Analysis

AI Investment Thesis

Data as of:Aug 7, 2026
|
Last calculated:Aug 7, 2026